An exploratory clinical trial for optimizing vancomycin therapy in Korean patients with MRSA infectio
Not Applicable
Recruiting
- Conditions
- Certain infectious and parasitic diseases
- Registration Number
- KCT0006018
- Lead Sponsor
- Kangwon National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
? Patients who have the ability to sign the consent form in accordance with GCP and corresponding laws
? Patients who are 19 years or older
? Patients who were decided to administer vancomycin for 7 days or more due to MRSA infection or within 3 days after initiation of vancomycin dosing
? Patient who understands the contents of the clinical research and provide their written informed consent forms
Exclusion Criteria
? Patients who co-administered vancomycin, except for the intravenous route. (e.g., per oral)
? Patients with contraindications for vancomycin (e.g., Anaphylaxis due to vancomycin)
? Patients in pregnancy or lactation
? Patients whom the researcher deemed inappropriate for clinical research participation
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacokinetic parameters (AUC, Ctrough)
- Secondary Outcome Measures
Name Time Method Occurrence of nephrotoxicity